Loading...
XNAS
SEER
Market cap120mUSD
Jul 09, Last price  
2.20USD
1D
0.92%
1Q
30.18%
IPO
-96.39%
Name

Seer Inc

Chart & Performance

D1W1MN
XNAS:SEER chart
P/E
P/S
7.50
EPS
Div Yield, %
Shrs. gr., 5y
-1.16%
Rev. gr., 5y
89.71%
Revenues
16m
+15.57%
0116,000656,0006,394,00014,685,00015,182,00013,947,00016,119,000
Net income
-74m
L-15.01%
-6,307,000-16,038,000-32,775,000-71,169,000-92,966,000-86,277,000-86,599,000-73,600,000
CFO
-44m
L-3.60%
-4,651,000-13,073,000-20,828,000-46,347,000-60,780,000-59,065,000-46,109,000-44,448,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
IPO date
Dec 04, 2020
Employees
164
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT